J 2023

Nonprocedural bleeding after left atrial appendage closure versus direct oral anticoagulants: A subanalysis of the randomized PRAGUE-17 trial

BRANNY, Marian, Pavel OSMANCIK, Petr KALA, Martin POLOCZEK, Dalibor HERMAN et. al.

Základní údaje

Originální název

Nonprocedural bleeding after left atrial appendage closure versus direct oral anticoagulants: A subanalysis of the randomized PRAGUE-17 trial

Autoři

BRANNY, Marian, Pavel OSMANCIK (garant), Petr KALA (203 Česká republika, domácí), Martin POLOCZEK (203 Česká republika, domácí), Dalibor HERMAN, Petr NEUZIL, Pavel HALA, Milos TABORSKY, Josef STASEK, Ludek HAMAN, Jan CHOVANCIK, Pavel CERVINKA, Jiri HOLY, Tomas KOVARNIK, David ZEMANEK, Stepan HAVRANEK, Vlastimil VANCURA, Petr PEICHL, Petr TOUSEK, Marek HOZMAN, Veronika LEKESOVA, Jiří JARKOVSKÝ (203 Česká republika, domácí), Martina NOVÁČKOVÁ (203 Česká republika, domácí), Klára BENEŠOVÁ (203 Česká republika, domácí), Petr Y WIDIMSKY a Vivek REDDY

Vydání

Journal of Cardiovascular Electrophysiology, HOBOKEN, Wiley-Blackwell, 2023, 1045-3873

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.700 v roce 2022

Kód RIV

RIV/00216224:14110/23:00132260

Organizační jednotka

Lékařská fakulta

UT WoS

001040991200001

Klíčová slova anglicky

atrial fibrillation; bleeding; gastrointestinal bleeding; left atrial appendage closure; major bleeding; nonvitamin K anticoagulants

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 15. 11. 2023 09:04, Mgr. Tereza Miškechová

Anotace

V originále

IntroductionObservational studies have shown low bleeding rates in patients with atrial fibrillation (AF) treated by left atrial appendage closure (LAAC); however, data from randomized studies are lacking. This study compared bleeding events among patients with AF treated by LAAC and nonvitamin K anticoagulants (NOAC). MethodsThe Prague-17 trial was a prospective, multicenter, randomized trial that compared LAAC to NOAC in high-risk AF patients. The primary endpoint was a composite of a cardioembolic event, cardiovascular death, and major and clinically relevant nonmajor bleeding (CRNMB) defined according to the International Society on Thrombosis and Hemostasis (ISTH). ResultsThe trial enrolled 402 patients (201 per arm), and the median follow-up was 3.5 (IQR 2.6-4.2) years. Bleeding occurred in 24 patients (29 events) and 32 patients (40 events) in the LAAC and NOAC groups, respectively. Six of the LAAC bleeding events were procedure/device-related. In the primary intention-to-treat analysis, LAAC was associated with similar rates of ISTH major or CRNMB (sHR 0.75, 95% CI 0.44-1.27, p = 0.28), but with a reduction in nonprocedural major or CRNMB (sHR 0.55, 95% CI 0.31-0.97, p = 0.039). This reduction for nonprocedural bleeding with LAAC was mainly driven by a reduced rate of CRNMB (sHR for major bleeding 0.69, 95% CI 0.34-1.39, p = .30; sHR for CRNMB 0.43, 95% CI 0.18-1.03, p = 0.059). History of bleeding was a predictor of bleeding during follow-up. Gastrointestinal bleeding was the most common bleeding site in both groups. ConclusionDuring the 4-year follow-up, LAAC was associated with less nonprocedural bleeding. The reduction is mainly driven by a decrease in CRNMB.